Impact of diabetic control on achieving sustained Virologic response in chronic HCV patients receiving direct-acting antivirals

Abstract EN

This study evaluated the effect of diabetic control on achieving sustained virologic response in patients with chronic hepatitis C virus infection who received direct-acting antivirals (Daclatasvir + Sofosbuvir ± Ribavirin).

It included 100 patients with chronic HCV infection (Treatment naive patients).

Patients were classified into 3 groups according to diabetic control; GI: non diabetics, GII : well controlled diabetics & GIII : poorly controlled diabetics.

All were subjected to clinical and laboratory examinations, abdominal ultrasonography and calculation of FIB-4 score.

PCR for HCV RNA was assessed prior to treatment, post treatment and 12 weeks post-treatment.

The results showed insignificant differences between all groups as regards sustained virologic response.

Overall sustained virologic response was achieved in 91 % of patients including 91.8 % of patients treated with Daclatasvir + Sofosbuvir and 89.7 % of those treated with Daclatasvir + Sofosbuvir + Ribavirin.